F00574 014 g002

F00574 014 g002



CLINICAL POINTERS


CLINICAL EXAMINATION


BASELINE INYESTIGATIONS



Risk behayiour/group


See opposiie


AJI


•    Contact wrth HfYendemic area

Recent arrivai $exuai tourisitopatriate Heanh-care worker BJood traretuston reclpłem

•    Sexualiy aclue

Men who have sex with men Commercial sex woiker Unproteded sex with numerous partners

•    mjection drug user

•    Partner d Hiv-lnfected person


KEY HISTORY POINTS


Confirmed diagnosis in risk group


HIV (assessing time ol HlV acguisition/likdihood of resi stance)


•    CD4C0unt

•    Virai load (VI)

•    Hepatite B (HBV) status

•    Iłepatios C (HCV) antibody

•    nv resistance test

•    Cervlcal smear in women

•    tfepatihs A (HAV) igG antibody

•    Toxopła$ma antibody

•    Cytomegakn/lrus (CMY) IgG antibody

•    Treponema serology

•    Genitounnary mediwie screen

C04 < 200 ceUs/mm’


•    Herpes zoster

•    Actlve tubcraitoss

•    Recurrent pneumococcal pneumofra

•    Demenba

•    B-cell lymphoma

•    Paul-Bunnell negative glandufer tever

•    Necrotlslng gingivitls

•    Other hiv symptomatic cfcsease (Bo* 14.5)

•    Other AJDS-detining dtsease (Box 14.6)


lnvestigations

•    Tt¥omt)ocytopenia/atypjcaityniphocyiosis

•    Lymphopenia

•    Pasitiye markers lor hepaiihs B. hepatits C or syphihs


•    Previous negative wv test

•    Hcstory consistenl with serocorwcrsion (p 400)

•    Known HfV-intected ex-/current partner

? On medcation

•    Eptsodes ot 'unsafe' sex m high risk srtuattons (e g saunas)

•    Previous antenatai screening

•    Mtstoiy d herpes zoster

General


•    Chesi X-ray

•    HCV-RNA

•    Cryptococcal antigen

•    Stoolforova,cystsandparasites

C04 < lOOcelłs/mm’


•    CMVPCR

•    Dilated fundoscopy

•    Electroencephaiogram (ECO

•    Mycobactenal Wood cultures


PRE-TEST COUNSELLING


Oiscuss purpose d test Carry out rtsk assessment Exptixe knowtedge and exptain naturai rustocy ot hiv

Oiscuss transmission and risk reduction Assess likety coptng strategy Explam test proceduro OMaln inlormed consent


i


LABORATORY CONFIRMATION


•    ftrthptace, residence. occupatlon

•    Tuberculosis: past history or contact

•    Travel history/animal contacis

•    Immunisation history (BCG. hepatflls A and B)

•    Recrealional drug use

•    Past sexuaiiy transmltied infecbons

•    Partner and cfokken

•    Others’ kncwledge ot status (to contact if needcd)

•    GP awareness and permission to inform


POST-TEST COUNSELLING


FURTHER ISSUES


On


Immunisations


Hepatibs A and hepatltis B if nonimmune

Pneumovax (at Iniuai dagnose and then 3-5-yearty)

Influenza (yearly)

Consrder tetanus booster (if injcction drug user)


Counsdlmg


Serology using commeroal enzyme-inked immunosorbent assay (ELISA) screening test'

Test resutt negatlve:

Second test 3 months atter last exposure

Test resutt positrve Resiit contirmed using two diflerent immunoassays aiktfor Western biot Second samplo checked Nucleic acid amplilication test7 łf: Serocoiwersion suspected Confirming vertical transmission


Test resutt negatńre

•    Oiscuss transmission and need for behaviour modilication

Sater sex, needie exchange

•    Advtse second test 3 months atter last exposure

•    Support ii uninlected partner Test resutt positive


Safe sex/behaviour modification Cryptospońdiai risk and need to boil water

Toxoptosma risk and sale handling ol catsłtter: undercooked meat Lwe vaccmes and travei Orerthe-counter medicines (1 on highty actwe anhretrowrai therapy (HAART) Plans for pregnancy


' Commonty lor HIV-1 antibody. i*V-2 antibody and p24 anbgsn.

1 Eg. pdymerase cham reaction (PCR) or branched-chain ONA assay.


•    Expłain signilicance and Impiicatlons d resutt

Fcar d disdosure Dłscrlmlnation^sociai re|ection

•    Organise urgent medcat follow-up

•    Assess copmg strategy

•    ProYide verbai and wrltten information

•    Oiscuss conhdenbaiity ssues

•    Organise emotionai and practical support (names/numbers)


Repeat tcsts


Treponemai antibody 3-4 times/year IBV markers every f-2 years HCV antibody every 1-2 years HBVs antibody m Immunised persons to assess need for booster Cemlcal smear yearty loxopiasma and CMV serology ii negatwe ritialty, yearty


<$> Elsevier. Boon et a!.: Dayidson^s Principles and Practice of Medicine 20e - www.studentconsult.com



Wyszukiwarka

Podobne podstrony:
F00574 019 g002 ©-© KEY FEATURES ON EXAMINATION OF COMMON RESPIRATORY CONDITIONSChronić obstructive
F00574 018 g002 o EXAMINATION OF THE ARTERIAL PULSE •    The character of the pulse i
F00574 022 g002 ABDOMINAL EXAMINATION: POSSIBLE FINDIN6S Left upper guadrant mass ?Spleen Edge 
Finał (clinical) examination results 2009 - 2012 Australia New
F00574 007 g002 © GET UP AND GO TEST Ask the patient to stand up from a sitting position, walk 10 m,
F00574 008 g002 lntravenous fluids Monitor displaying biood pressure/ atnai pressure/heart
F00574 014 f001 Stagc Steps in rcplication Drug targcts 1 Attachment to CD4 receptor 2 Binding to
F00574 014 g001 Oropharynx Teeth Periodontitis Mucous membranes Herpes simplex Aphthous ui
F00574 023 g002 CAUSES OF A8N0RMAL LtVER SI2E o FLAPPING TREMOR Jerky forward morements every 2-3 se
F00574 024 g002 o ANAEMIA The box shows the symptoms and signs that will help to indicate the d
Examinati.pn NpUccEmgrammfi nŁDegatcd (limisj Group Pistribution; Group- A: Physics. Chemistry. Boła
F00574 003 f007 □ oo 0 d. 50 y Małe. female. unknown sex Clinically affected (specify condition in k
F00574 005 f015 Total - 0 Total = 1 Total £ 2 Low risk Medium risk High risk • Routine clinica
F00574 018 f017 Stable angina Unstable angina Pathophysiology Clinical features Risk assessment •
F00574 007 f002 Changes with ageing Clinical conseguences CNS •    Neuronal loss •
65679 Tabela 1 labie L Baseline Clinical and Angiographic Core Laboratory Characteristics.* Charac

więcej podobnych podstron